QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Core Insights - The law firm Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of uniQure N.V. [1] - On November 3, 2025, uniQure announced that the FDA indicated insufficient evidence from its AMT-130 gene therapy studies to support its Biologics License Application (BLA) [2] - Following this announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [2] Company Developments - uniQure's AMT-130 is an investigational gene therapy aimed at treating Huntington's disease [2] - The FDA's feedback suggests that data from Phase I/II studies may not be adequate for BLA submission, leading to uncertainty regarding the timing of the application [2] Legal and Regulatory Context - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions related to securities fraud and breaches of fiduciary duties, having recovered billions for investors [3]